🇺🇸 Sunitinib Malate (SU011248) in United States

56 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Nausea — 11 reports (19.64%)
  2. Vomiting — 9 reports (16.07%)
  3. Diarrhoea — 6 reports (10.71%)
  4. Acute Kidney Injury — 5 reports (8.93%)
  5. Dehydration — 5 reports (8.93%)
  6. Anaemia — 4 reports (7.14%)
  7. Asthenia — 4 reports (7.14%)
  8. Disease Progression — 4 reports (7.14%)
  9. Hypotension — 4 reports (7.14%)
  10. Pleural Effusion — 4 reports (7.14%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Sunitinib Malate (SU011248) approved in United States?

Sunitinib Malate (SU011248) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Sunitinib Malate (SU011248) in United States?

H. Lee Moffitt Cancer Center and Research Institute is the originator. The local marketing authorisation holder may differ — check the official source linked above.